前交叉韧带重建使用骨-髌腱-骨同种异体移植物较自体移植物翻修风险增加
该回顾性队列研究基于Kaiser Permanente ACLR登记系统,比较骨-髌腱-骨(BPTB)自体移植物与同种异体移植物重建前交叉韧带后的无菌性翻修风险。共纳入5586例患者,同种异体移植物组调整后翻修风险显著高于自体移植物组(HR 4.54;95%CI 3.03-6.79;P<.001),且各处理方式及不同年龄组风险一致升高。作者建议外科医生和患者知晓使用BPTB同种异体移植物时翻修风险增加。
要点
- BPTB同种异体移植物组2年累积翻修率为4.1%(95%CI 2.9%-5.9%),自体移植物组为1.7%(95%CI 1.3%-2.2%)。
- 调整年龄、性别和种族后,同种异体移植物组翻修风险显著高于自体移植物组(HR 4.54;95%CI 3.03-6.79;P<.001)。
- 无论同种异体移植物是否经辐射(<1.8 Mrad或≥1.8 Mrad)或化学处理,翻修风险升高一致;年轻和年长患者中差异也一致。
核心结论
- 使用BPTB同种异体移植物行ACLR时,调整后翻修风险较BPTB自体移植物高4.54倍。
- 同种异体移植物经高剂量或低剂量辐射、化学处理或未处理,翻修风险差异不大。
- 年轻和年长患者中翻修风险差异一致。
- 作者认为外科医生和患者应知晓使用BPTB同种异体移植物行ACLR时翻修风险增加。
研究设计与样本
- 回顾性队列研究,证据等级2,使用Kaiser Permanente ACLR登记系统前瞻性收集的数据。
- 纳入接受初次单侧BPTB自体移植物或BPTB同种异体移植物ACLR的患者,共5586例。
- 暴露因素为移植物类型及同种异体移植物处理方式(未处理、<1.8 Mrad、≥1.8 Mrad辐射)。
- 年龄(≤21岁和≥22岁)作为效应修饰因素评估,分析调整年龄、性别和种族。
- 采用Kaplan-Meier曲线和Cox比例风险模型,提供风险比(HR)和95%CI。
主要发现
- BPTB队列共5586例患者:3783例(67.7%)为男性,2359例(42.2%)为白人,1029例(18.4%)使用同种异体移植物(未处理155例;<1.8 Mrad 525例;≥1.8 Mrad 288例),4557例(81.6%)使用自体移植物。
- 同种异体移植物病例中位年龄34.9岁(IQR 25.4-44.0),自体移植物病例中位年龄22.0岁(IQR 17.6-30.0)。
- 2年累积翻修率估计值:同种异体移植物组4.1%(95%CI 2.9%-5.9%),自体移植物组1.7%(95%CI 1.3%-2.2%)。
- BPTB同种异体移植物调整后翻修风险显著高于BPTB自体移植物(HR 4.54;95%CI 3.03-6.79;P<.001)。
- 与自体移植物相比,所有同种异体移植物处理方式的翻修风险升高一致,且无论年龄,同种异体移植物患者中风险均一致升高。
关键数值与推荐
- 2年累积翻修率:同种异体移植物组4.1%(95%CI 2.9%-5.9%)vs 自体移植物组1.7%(95%CI 1.3%-2.2%)。
- 调整后翻修风险:BPTB同种异体移植物组HR 4.54(95%CI 3.03-6.79;P<.001),以BPTB自体移植物组为参照。
- 同种异体移植物处理方式亚组:未处理155例、<1.8 Mrad 525例、≥1.8 Mrad 288例,与自体移植物相比翻修风险均一致升高。
临床怎么用
- 作者认为,外科医生和患者应知晓使用BPTB同种异体移植物行ACLR时翻修风险增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of allograft tissue for anterior cruciate ligament reconstruction (ACLR) remains controversial. PURPOSE: To compare the risk of aseptic revision between bone-patellar tendon-bone (BPTB) autografts and BPTB allografts. STUDY DESIGN: Cohort study; Level of evidence, 2. METHODS: A retrospective cohort study of prospectively collected data was conducted using the Kaiser Permanente ACLR Registry. A cohort of patients who underwent primary unilateral ACLR with BPTB autografts and BPTB allografts was identified. Aseptic revision was the endpoint. The type of graft and allograft processing method (nonprocessed, <1.8-Mrad, and ≥1.8-Mrad irradiation) were the exposures of interest evaluated. Age (≤21 and ≥22 years) was evaluated as an effect modifier. Analyses were adjusted for age, sex, and race. Kaplan-Meier curves and Cox proportional hazards models were employed. Hazard ratios (HRs) and 95% CIs are provided. RESULTS: The BPTB cohort consisted of 5586 patients: 3783 (67.7%) were male, 2359 (42.2%) were white, 1029 (18.4%) had allografts (nonprocessed: 155; <1.8 Mrad: 525; ≥1.8 Mrad: 288), and 4557 (81.6%) had autografts. The median age was 34.9 years (interquartile range [IQR], 25.4-44.0) for allograft cases and 22.0 years (IQR, 17.6-30.0) for autograft cases. The estimated cumulative revision rate at 2 years was 4.1% (95% CI, 2.9%-5.9%) for allografts and 1.7% (95% CI, 1.3%-2.2%) for autografts. BPTB allografts had a significantly higher adjusted risk of revision than BPTB autografts (HR, 4.54; 95% CI, 3.03-6.79; P < .001). This higher risk of revision was consistent with all allograft processing methods when compared with autografts and was also consistently higher in patients with allografts regardless of age. CONCLUSION: When BPTB allograft tissue was used for ACLR, an overall 4.54 times adjusted higher risk of revision was observed compared with surgery performed with a BPTB autograft. Whether the tissue was irradiated with either high- or low-dose radiation, chemically processed, or not processed at all made little difference in the risk of revision. The differences in the revision risk were also consistent in younger and older patients. Surgeons and patients should be aware of the increased risk of revision when a BPTB allograft is used for ACLR.
引用
- Maletis GB, Chen J, Inacio MCS, et al. Increased Risk of Revision After Anterior Cruciate Ligament Reconstruction With Bone-Patellar Tendon-Bone Allografts Compared With Autografts. Am J Sports Med. 2017. PMID: 28277740. doi:10.1177/0363546517690386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。